Weekly Roundup: Events, events & more events
Hansa Biopharma’s ConfIdeS Phase 3 abstract selected for ‘What’s Hot, What’s New’ plenary at ATC 2026
Hansa Biopharma AB, announced on Thursday that the ConfIdeS Phase 3 abstract titled “Superior 1-year eGFR Among Highly Sensitized Patients Desensitized with Imlifidase Compared to Control” had been selected to be highlighted at the closing plenary session “What’s Hot, What’s New” at the American Transplant Congress (ATC) 2026, which took place in Boston on June 24, 2026.
The Company also held its Capital Markets Day in New York on Thursday, which featured medical presentations on the pivotal U.S. Phase 3 ConfIdeS study, as well as findings from the European Post‑Authorisation Efficacy Study (PAES) with Idefirix/imlifidase in Europe. Hansa executives also presented the strategy and market opportunity for Hansa Biopharma’s pre-launch and commercialisation preparations ahead of a potential U.S. approval.
BioBabraham Symposium – Babraham Research Campus, Cambridge | 24th June 2026
The Optimum team had a wonderful time attending the June BioBabraham Symposium, which provided a fantastic opportunity to learn more about the innovative science emerging from Campus, and the collaborative spirit that defines the Babraham ecosystem. Our CEO, Mary Clark, moderated the closing panel discussion ‘Attracting investors in a turbulent market,’ where leading investors shared valuable insights on today’s market, which led to an engaging and thoughtful discussion.
EQT Life Sciences & EY Annual Biotech Update 2026
Our very own Mary Clark and Zoe Bolt attended this year’s EQT Annual Biotech Update – a day dedicated to innovation, insight and dialogue in life sciences. The event explored key themes shaping the biotech industry, including developments in technology, the geopolitical environment and the broader innovation ecosystem.
A particularly interesting panel focused on women’s health, featuring Dr Helen O’Neill, Founder & CEO of Hertility Health, a women’s health company pioneering at-home hormone and fertility testing, providing data-driven insights and access to specialist care to help women better understand their reproductive health.
📺Optimum TV
Biotech’s coming of age
With Melanie Senior, journalist
Biotech is back. M&A is booming, IPOs are picking up, the XBI hovers near an all-time-high. But the mood is more sober than jubilant, says journalist Melanie Senior in her latest Nature Biotechnology feature on the state of the life science investment market. Watch Melanie in #OptimumTV’s latest Thought Leaders episode as she dissects what’s changed – and what hasn’t – over the last 12 months.
Watch here:
Read Melanie’s recent articles Biotech’s Coming of Age and Programming Biology: Next-Gen AI Firms Raise Billions To Design Better Medicines
👥Industry events
On Helix – Cambridge | 9th Jul 2026
This July, One Nucleus presents ON Helix - Disrupting Bio Innovation.
A one-day conference in Cambridge spotlighting and discussing the breakthrough technologies, policies and business models that are shaping the drug discovery and development landscape. This is an excellent opportunity to connect with the pioneers leading this next wave of disruptive innovation and ensure you stay ahead in a rapidly evolving space.
Optimum is a proud supporter of One Nucleus events and is happy to share an exclusive 10% F&F discount. Please get in touch if you would like to use this or connect with the team there!
Optimum’s 18th Annual Healthcare Investor Conference – London | 8th Oct 2026
Maximising Europe’s Potential – The theme of Optimum’s Annual Healthcare Investor Conference 2026.
The invitation only event takes place on Thursday 8th October and features leading speakers from the healthcare and investment communities. Register your interest in attending today: https://www.optimumcomms.com/irconference2026/
Follow us on LinkedIn to hear updates on speakers and panellists, as they are announced.
That’s all folks! To stay in the know – subscribe to Optimum’s weekly wrap-up today!
